Sutrim forte

Quick links

Choose a section

Quick links to important sections

Advertisements

Sutrim forte

Advertisements

Overview of Sutrim forte

Property Description
Active Ingredient Sulfamethoxazole and Trimethoprim
Form Tablet, Oral Suspension, Intravenous Solution
Pharmacological Class Combination Antibiotic (Antimicrobial Agent)
Common Use Treating Bacterial Infections
Origin Synthetic Antibacterial

Sutrim forte is a prescription-only, synthetic antibacterial medicine, known generically as Co-trimoxazole, used for systemic infection control. It is a fixed-dose combination product containing two primary active pharmaceutical ingredients: Sulfamethoxazole (a sulfonamide antibiotic) and Trimethoprim (a dihydrofolate reductase inhibitor). This pairing creates a dual-action agent, distinguishing it from single-substance antibiotics. This combination is available in multiple dosage forms, including the standard Oral Tablet (often in a Forte or Double Strength concentration), the Oral Suspension for liquid administration, and the Solution for Intravenous Injection.


Sutrim forte's Class and General Purpose

Sutrim forte is classified as an Antibiotic (Antimicrobial Agent) that achieves its effect through a unique synergistic action against susceptible bacteria. The general purpose of this medicine is to eliminate harmful bacterial infections by exploiting the dual mechanism. The combined use of these two agents is widely clinically recognized for its increased efficacy against a broad spectrum of microorganisms compared to either ingredient alone. The combined effect involves the simultaneous blockade of two consecutive steps in the bacteria’s essential pathway for manufacturing folic acid. By halting this process, which is vital for them to create DNA and replicate, the medicine effectively disrupts the bacteria's growth, reproduction, and survival.

Regulatory References

  1. National Center for Biotechnology Information
  2. synthetic antibacterial
  3. fixed-dose combination product
  4. Sulfamethoxazole
  5. Trimethoprim
  6. folic acid
  7. DNA
Advertisements

What side effects are possible with Sutrim forte?

Possible Side Effects and Safety Information

Sutrim forte, a combination of sulfamethoxazole and trimethoprim, is associated with a spectrum of potential adverse reactions, ranging from common to severe and life-threatening events. The overall safety profile necessitates careful patient monitoring.

Adverse Reaction Category Examples of Documented Reactions
Common Nausea, vomiting, loss of appetite (anorexia), diarrhea, and skin rash.
Serious / Clinically Significant Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Fatalities have been reported.
Organ System Risks Blood dyscrasias (e.g., agranulocytosis, aplastic anemia, leukopenia), fulminant hepatic necrosis, acute renal failure, Clostridioides difficile-associated diarrhea, and hypersensitivity reactions of the respiratory tract (e.g., pulmonary infiltrates).

Safety Considerations and Contraindications

Sutrim forte is contraindicated in patients with a known hypersensitivity to either trimethoprim or sulfonamides, documented megaloblastic anemia due to folate deficiency, marked hepatic damage, or severe renal insufficiency when kidney function cannot be properly monitored. It must not be administered to infants less than two months of age due to the risk of kernicterus. Use during pregnancy and in nursing mothers is generally avoided as sulfonamides cross the placenta and are excreted in milk, carrying a risk of kernicterus.

Caution is advised in elderly patients, who may be at increased risk for severe adverse effects like hyperkalemia and specific blood disorders. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at risk for hemolytic anemia. Treatment requires immediate discontinuation at the first appearance of skin rash or any sign of a serious reaction, as these may precede a more severe, life-threatening event.

Advertisements

Overdose and Emergency Response

Suspected overdosage with Sutrim forte requires immediately seeking emergency medical attention. Official regulatory guidance mandates contacting emergency services or a Poison Help Line when an overdose is suspected.

Documented Manifestations and Severe Outcomes

Acute overdosage with the Sulfamethoxazole and Trimethoprim combination may present with initial clinical signs including vomiting, loss of appetite, fever, headache, and confusion. More severe manifestations documented in regulatory labeling can involve the yellowing of the skin or eyes (jaundice), blood in the urine (hematuria), and loss of consciousness.

Serious physiological outcomes relate to the components' specific toxicities. The Trimethoprim component carries a risk for severe bone marrow depression, which may lead to life-threatening hematologic conditions. The Sulfamethoxazole component may lead to crystalluria, resulting in toxic nephrosis and renal complications, a risk heightened in patients with pre-existing severely impaired renal function.

Officially Described Management

Treatment for overdosage is specified as entirely symptomatic and supportive. If bone marrow depression is detected, the official label directs the use of Leucovorin (folinic acid) as an intervention. Other procedures include fluid administration and potentially gastric lavage to aid clearance. Efforts to prevent complications such as crystalluria through urine alkalinization may be initiated. Hospital monitoring for hematologic status and plasma drug levels may be required to manage the overdosage effectively.

Advertisements

Therapeutic Uses of Sutrim forte

What Sutrim Forte Treats: Main Uses and Benefits

Sutrim forte, an anti-infective medication, is applied across domains where additional symptomatic support is needed and used in situations involving certain distressing symptoms. This medicine is commonly used to help with conditions presenting with systemic or localized discomfort. This focus on patient experience is summarized by the principle:

“It contributes to easing the overall symptom burden during periods of heightened symptoms.”

This combination assists in managing symptom clusters that may become intense or disruptive, associated with common conditions such as Urinary Tract Infections (UTIs), acute exacerbations of chronic bronchitis, specific types of pneumonia, and gastrointestinal issues like traveler's diarrhea and shigellosis. It may also be part of symptomatic management for Pneumocystis jirovecii pneumonia (PJP), a clinical scenario relevant in contexts involving heightened systemic burden, often for individuals who are immunosuppressed.

Overall, Sutrim forte supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases.

Quick Fact: Supportive symptom management for Symptoms Related to Inflammatory States

Regulatory References

  1. NIH MedlinePlus Drug Information on Co-trimoxazole
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Sutrim forte?

This section outlines the officially documented population eligibility rules for Sulfamethoxazole/Trimethoprim (Sutrim forte), as defined by regulatory authorities.


Populations for Whom Use is Contraindicated

Use of Sutrim forte is absolutely contraindicated in several populations, meaning it must not be used:

  • Infants less than two months of age.
  • Patients with documented megaloblastic anemia due to folate deficiency.
  • Individuals with known hypersensitivity to trimethoprim, sulfonamides, or excipients.
  • Patients with severe organ impairment, specifically marked hepatic damage or severe renal insufficiency when monitoring is not possible.
  • Pregnant patients and nursing mothers.

Age-Based and Conditional Eligibility

Age Group Eligibility Status
Children Established for those 2 months of age and older.
Older Adults Established, but requires close monitoring of kidney and liver function due to increased susceptibility to adverse reactions.

Use is restricted or requires special caution in patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency, those at risk of folate deficiency (such as the elderly or malnourished), and patients with impaired renal function requiring necessary dosage adjustments.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Sutrim forte (Co-trimoxazole), based strictly on government regulatory labeling, concerning co-administration with other substances.

Interaction Classification Relevant Substance or Category
Formally Contraindicated Dofetilide: Co-administration is prohibited due to the risk of increased plasma levels of Dofetilide and serious cardiac arrhythmias.
Prohibited (Contextual) Leucovorin: Concurrent use is advised against when treating Pneumocystis jirovecii pneumonia due to documented increased mortality.

Official Interaction Statements

  • Exposure Modification: Sutrim forte is documented to increase the plasma concentrations of certain medicines, including Digoxin, Phenytoin, and Methotrexate, due to inhibition of metabolic enzymes or renal transporters. Elevated levels of these agents may result from the medicine's effect on CYP2C9 and the renal transporter OCT2.
  • Pharmacodynamic Potentiation: The combination significantly enhances the effect of Warfarin, leading to prolonged International Normalized Ratio (INR), and increases the risk of hyperkalemia when used with agents like ACE Inhibitors.
  • Population-Specific Notes: Regulatory documents specify a heightened risk of blood disorders (e.g., thrombocytopenia with purpura) in elderly patients receiving concurrent Thiazide diuretics. Renal transplant patients receiving Cyclosporine may experience increased nephrotoxicity.
  • Other Agents: The medicine interacts with oral hypoglycemic agents (like Glipizide) and anti-folate agents (like Methotrexate) where concomitant use is noted to increase specific toxicity risks.
Advertisements

Mechanism of Action

Sutrim forte utilizes a highly specific strategy of sequential metabolic blockade designed to inhibit microbial proliferation. The mechanism relies on the combined action of Sulfamethoxazole and Trimethoprim, which target two distinct, consecutive enzymes required for microbial proliferation. Sulfamethoxazole acts as a competitive inhibitor of Dihydropteroate Synthase (DHPS), while Trimethoprim inhibits Dihydrofolate Reductase (DHFR), effectively blocking the formation of the necessary activated folate.

This unique dual interference creates a synergistic effect by causing a profound depletion of Tetrahydrofolic Acid (THF). THF is required for synthesizing purine and thymidine nucleotides, the fundamental building blocks of DNA and RNA. Their absence immediately halts the cell's ability to grow and replicate. This metabolic failure shifts the combined action from a simple growth-arresting effect (bacteriostatic) to a bactericidal effect.

The mechanism exploits the reliance of susceptible microbes on de novo folate synthesis. However, Trimethoprim can weakly inhibit the Epithelial Sodium Channel (ENaC) in the human kidney at high concentrations, a non-target mechanism that can modulate potassium excretion.

Advertisements

Dosage and Administration Information

Sutrim forte is a brand name for the combination product sulfamethoxazole and trimethoprim, and its use must strictly follow the instructions defined in official labeling. The administration and dosage are determined by the form used, the patient's age, and kidney function.

Official Administration Routes and Preparation

  • Oral: Tablets (e.g., Double Strength, 800 mg sulfamethoxazole / 160 mg trimethoprim) and oral suspension are taken by mouth. The medicine may be taken with or without food, but official guidance recommends taking it with a full glass of water, and maintaining adequate fluid intake is advised.
  • Intravenous (IV) Infusion: The injection concentrate must always be diluted before use, typically in 5% Dextrose in Water (D5W). It must be administered by slow intravenous infusion over a period of 60 to 90 minutes; rapid infusion or bolus injection is strictly forbidden.

Standard Dosing and Frequency

  • Standard Adult Dosing: A common standard regimen is one Double Strength tablet (800 mg/160 mg) taken every 12 hours (b.i.d.).
  • Pediatric Dosing: For children 2 months of age and older, the dose is weight-based, usually calculated on the trimethoprim (TMP) component, and administered in divided doses every 6, 8, or 12 hours, depending on the total daily dose required.

Population-Specific Adjustments

  • Renal Impairment: Dosing must be adjusted based on the patient's Creatinine Clearance (CrCl). For CrCl between 15 and 30 mL/min, the dosage is reduced to half the usual regimen. Use is generally not recommended for CrCl less than 15 mL/min.
  • Course Duration: The length of treatment is specific to the condition, typically ranging from 5 to 14 days, and should be completed as prescribed.
Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Sutrim forte

Evidence for Use in Acute Urinary Tract Infections (UTIs)

Sutrim forte was studied for use in conditions characterized by acute or disruptive episodes, such as urinary tract infections. Studies conducted during periods of increased symptom activity have included large-scale randomized controlled trials (RCTs), comparative trials against other treatments, and systematic reviews. Researchers examined primary outcomes related to physical discomfort and outcomes reflecting the elimination of the causative bacteria (microbiological eradication). These studies primarily included non-pregnant adults with uncomplicated lower UTIs, patients with more complicated infections, and certain pediatric groups (excluding infants).

Studies reported measurements of microbiological eradication across various trial settings, particularly in older evidence. Studies reported measurements of symptom resolution time in patients with acute cystitis following administration of the combination agent. Uncertainty remains regarding how widespread antibiotic resistance affects the use of the agent.


Evidence for Use in Acute Bronchitis and Respiratory Infections

Sutrim forte was studied for use in research contexts involving fluctuating or unstable symptoms, such as acute exacerbations of chronic bronchitis. Studies monitored patient-reported outcomes describing perceived discomfort related to respiratory symptoms like cough and sputum production. Research examined the use of the combination agent in adults with chronic bronchitis experiencing periods of heightened symptoms, often comparing it against placebo or other agents. Follow-up durations were limited, often covering only the 10-to-14-day treatment window. This means there is limited information for long-term outcomes tracking what happens to patients beyond the initial episode.


Evidence for Use in Specialized Systemic Infections (PJP)

Research describes the use of Sutrim forte in specific, high-risk scenarios, such as the treatment and prevention of Pneumocystis jirovecii pneumonia (PJP). Studies explored this condition, which is characterized by heightened systemic burden and was primarily observed in immunosuppressed individuals. Findings from trials and long-term cohort studies describe observed outcomes related to patient survival when the agent was used for acute PJP treatment. A key limitation is that these results apply almost exclusively to the immunosuppressed populations studied (e.g., those with HIV or transplant recipients), limiting context for the general population.

Key Studies & References

  1. Sulfamethoxazole and Trimethoprim (Co-trimoxazole) Drug Information – MedlinePlus
  2. Pneumocystis Pneumonia: Adult and Adolescent Opportunistic Infection Guidelines – NIH Clinical Info
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sutrim forte (FAQ)

Q: Why is it called 'forte'? Does that mean it's a stronger dose?

A: The term 'Forte' is used in official labeling to designate a double-strength concentration of the medicine. This means the tablet or dosage form contains a higher amount of both active ingredients (sulfamethoxazole and trimethoprim) compared to a regular-strength product.

Q: Are there any signs of a serious allergic reaction to look out for?

A: Serious signs may include general symptoms such as fever, swollen glands, joint pain, muscle aches, or confusion. Regulatory documents state that treatment must be discontinued immediately at the first sign of a skin rash or other serious reaction, as these may precede a severe, life-threatening event.

Q: Is Sutrim forte safe to take if I have kidney problems?

A: According to official documents, the medicine is contraindicated (should not be used) if a patient has severe kidney disease that cannot be properly monitored. For cases of less severe kidney impairment, regulatory documents indicate that dosage adjustment is necessary, with the regimen determined by a healthcare professional based on the individual's kidney function.

Q: Why does Sutrim forte sometimes cause a rash, and how common is it?

A: Official adverse reaction reports list a skin rash as a common side effect. The rash is considered a potential sign of a hypersensitivity (allergic) reaction, and its presence requires immediate discontinuation as it can lead to more serious skin conditions.

Q: Is it possible to develop a resistance to Sutrim forte over time?

A: Yes. As an antibacterial drug, the risk of developing drug-resistant bacteria is a documented concern in official materials. Regulatory guidance emphasizes that the full course of therapy, as prescribed, is crucial for limiting the emergence of drug-resistant bacteria.

Q: Is there any research on long-term effects of taking this combination drug?

A: The medication is typically prescribed for short-term use, with courses often lasting between 5 to 14 days for acute infections. Long-term use (prophylaxis) is primarily reserved for preventing specific, serious conditions in immunosuppressed patients and requires very close clinical monitoring.

Q: How should I store Sutrim forte tablets or liquid suspension?

A: Both the tablets and the liquid suspension should be kept at a controlled room temperature, which is typically between 20 C and 25 C (68 F and 77 F). Official guidance advises that the liquid oral suspension must be shaken well before each use.

Q: Does Sutrim forte have any known effects on blood sugar levels?

A: Official adverse event reports indicate that the medicine may cause changes in blood sugar, including the potential for hypoglycemia (low blood sugar). It is also known to interact with medicines used to treat diabetes.

Q: Does this medicine interact with medications for high blood pressure?

A: Official drug interaction reports confirm potential interactions with certain heart and blood pressure medications. Specifically, co-administration with ACE inhibitors and certain diuretics (water pills) may increase the risk of high potassium levels (hyperkalemia).

Q: Can it be used to prevent certain infections, or only to treat them?

A: The medicine is approved for both the treatment of existing infections and the prevention (prophylaxis) of specific serious infections. Official indications confirm its use for prevention, particularly for Pneumocystis pneumonia in individuals with suppressed immune systems.

Q: What does the research say about Sutrim forte's effectiveness compared to no treatment?

A: Clinical studies supporting official labeling report that the medicine achieved defined clinical and microbiological outcomes in treating the bacterial infections for which it is indicated.

Q: How is the medicine eliminated from the body?

A: The active ingredients are primarily eliminated from the body by the kidneys. This process involves filtration and secretion, which is why patients with impaired kidney function require dosage adjustments.

Q: How quickly does Sutrim forte typically start to work after the first dose?

A: Official information regarding the medicine's activity indicates that the peak blood levels of the components generally occur 1 to 4 hours after the first oral dose. This indicates the time required for the body to absorb the drug and reach its maximum concentration in the bloodstream.

Q: What happens if I miss a dose of Sutrim forte?

A: Official patient advice emphasizes that adherence to the full prescribed course is important to support the best possible outcome. Failure to take the medicine exactly as directed can increase the risk of developing resistant bacteria.

Q: What is the guidance on sun exposure while on this medication?

A: The medicine can cause photosensitivity, which means it increases your skin's sensitivity to sunlight and ultraviolet (UV) light. Regulatory guidance mentions that exposure to sunlight and artificial UV light (like tanning beds) should be minimized, and measures such as using sunscreen or protective clothing are noted as necessary when patients are outdoors.

Q: What does 'photosensitivity' mean in the context of this drug?

A: Photosensitivity, in the context of this medicine, means that the drug can increase the skin's reaction to sunlight. This can lead to an exaggerated or severe sunburn or rash even after brief sun exposure, and patients should take precautions.

Q: Can Sutrim forte interact with common anti-depressants or anxiety medications?

A: Yes, according to official drug interaction sections. Patients using medicine to treat depression or seizures may require additional clinical monitoring or more frequent medical tests, as this combination may affect the blood levels of those medications.

Q: Why is adequate fluid intake mentioned in connection with Sutrim forte?

A: Official documents advise maintaining adequate fluid intake because drinking extra water helps to prevent specific unwanted effects in the urinary system. This helps to prevent the formation of crystals in the urine (crystalluria).

Q: Is it normal to feel dizzy or tired when taking this medicine?

A: Simple dizziness or tiredness are not generally listed as common side effects in the official label. However, regulatory documents do list central nervous system effects such as headache, and in rare, more severe adverse reactions, confusion has been reported.

Q: What happens if I accidentally take two doses at once?

A: In the event of an accidental overdose, symptoms can include loss of appetite, vomiting, fever, blood in the urine, confusion, or loss of consciousness. Regulatory documents state that overdose symptoms require immediate medical attention.

Q: Is Sutrim forte the same as the drug commonly known as Bactrim or Septra?

A: Yes. Sutrim forte is a brand name for the combination of sulfamethoxazole and trimethoprim. Official sources confirm that this combination is also commonly marketed and known under various other brand names, including Bactrim and Septra.

Q: Why do official guidelines restrict its use for certain infections?

A: Official guidelines state that this medicine should only be used to treat infections that are known or strongly suspected to be caused by susceptible bacteria. This restriction is primarily to preserve the drug's effectiveness and to avoid promoting the development of drug-resistant bacteria.

Q: How long after finishing the prescription is the drug out of my system?

A: Official pharmacokinetics data show that the average serum half-lives of the components range from about 8 to 10 hours. Based on this rate, detectable amounts of the medicine may be present in the blood for up to 24 hours after a dose.

Q: What should I do if my symptoms do not improve after a few days of use?

A: Official patient counseling information indicates that a healthcare provider should be contacted if symptoms do not improve as expected or if they worsen.

Advertisements

How should Sutrim forte be stored and disposed of?

How to Store and Dispose of Sutrim Forte (Sulfamethoxazole and Trimethoprim DS Tablets)

Storage and disposal of Sutrim Forte must strictly adhere to the conditions mandated by regulatory authorities to ensure the medicine retains its intended stability.

Required Storage Conditions

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Permitted temperature excursions range from 15 C to 30 C (59 F to 86 F). The product must be kept in the original container and the container must remain tightly closed.

For safety, the medication must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Sutrim Forte must be disposed of according to local regulations. Patients should utilize drug take-back programs where available, as official guidance advises against flushing the medicine down the toilet or placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sutrim forte found in:

A-Z Index: